AFM
ZVSA

Anson Funds Management’s ZyVersa Therapeutics ZVSA Stock Holding History

Anson Funds Management’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,067
Closed -$145K – 217
2023
Q4 		$145K Buy
+16,067
New +$452K 0.02% 152

Other funds holding ZVSA

TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Anson Funds Management's ZVSA Position: Q1 2024 in Review

Anson Funds Management sold out of ZyVersa Therapeutics (ZVSA) in Q1 2024, closing a stake of 16,067 shares — an estimated $145K sold.

Anson Funds Management first reported a position in ZVSA in Q4 2023 and held it in 1 quarter. The position peaked at $145K in Q4 2023. 7 funds tracked by Wall St. Rank hold ZVSA as of Q1 2024.

  • Anson Funds Management reported no remaining ZyVersa Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Anson Funds Management sold 16,067 ZyVersa Therapeutics shares in Q1 2024, an estimated $145K.
  • Anson Funds Management first reported a position in ZyVersa Therapeutics in Q4 2023 and held it in 1 quarter.
  • Anson Funds Management's ZyVersa Therapeutics position peaked at $145K in Q4 2023.
  • 7 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q1 2024.

Based on Anson Funds Management's 13F filing for Q1 2024, filed 14 May 2024.